PHOSPHO1 is a skeletal regulator of insulin resistance and obesity.
PHOSPHO1 is a skeletal regulator of insulin resistance and obesity.
复制标题
DOI:
10.1186/s12915-020-00880-7
复制
发表时间:
2020-10-22
期刊:
影响因子:
5.4
通讯作者:
Farquharson C
中科院分区:
文献类型:
--
作者:
Suchacki KJ;Morton NM;Vary C;Huesa C;Yadav MC;Thomas BJ;Turban S;Bunger L;Ball D;Barrios-Llerena ME;Guntur AR;Khavandgar Z;Cawthorn WP;Ferron M;Karsenty G;Murshed M;Rosen CJ;MacRae VE;Millán JL;Farquharson C
The classical functions of the skeleton encompass locomotion, protection and mineral homeostasis. However, cell-specific gene deletions in the mouse and human genetic studies have identified the skeleton as a key endocrine regulator of metabolism. The bone-specific phosphatase, Phosphatase, Orphan 1 (PHOSPHO1), which is indispensable for bone mineralisation, has been recently implicated in the regulation of energy metabolism in humans, but its role in systemic metabolism remains unclear. Here, we probe the mechanism underlying metabolic regulation by analysing Phospho1 mutant mice. Phospho1−/− mice exhibited improved basal glucose homeostasis and resisted high-fat-diet-induced weight gain and diabetes. The metabolic protection in Phospho1−/− mice was manifested in the absence of altered levels of osteocalcin. Osteoblasts isolated from Phospho1−/− mice were enriched for genes associated with energy metabolism and diabetes; Phospho1 both directly and indirectly interacted with genes associated with glucose transport and insulin receptor signalling. Canonical thermogenesis via brown adipose tissue did not underlie the metabolic protection observed in adult Phospho1−/− mice. However, the decreased serum choline levels in Phospho1−/− mice were normalised by feeding a 2% choline rich diet resulting in a normalisation in insulin sensitivity and fat mass. We show that mice lacking the bone mineralisation enzyme PHOSPHO1 exhibit improved basal glucose homeostasis and resist high-fat-diet-induced weight gain and diabetes. This study identifies PHOSPHO1 as a potential bone-derived therapeutic target for the treatment of obesity and diabetes.
登录
查看更多内容
影响因子:
64.5
作者:
Ferron M;Wei J;Yoshizawa T;Del Fattore A;DePinho RA;Teti A;Ducy P;Karsenty G
通讯作者:
Karsenty G
DOI:
10.1359/jbmr.091023
发表时间:
2010-04
期刊:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
影响因子:
--
作者:
Ciancaglini P;Yadav MC;Simão AM;Narisawa S;Pizauro JM;Farquharson C;Hoylaerts MF;Millán JL
通讯作者:
Millán JL
影响因子:
2.4
作者:
Boyde, Alan;Staines, Katherine A.;Farquharson, Colin
通讯作者:
Farquharson, Colin
影响因子:
3
作者:
Bonneau, Jessica;Ferland, Guylaine;Ferron, Mathieu
通讯作者:
Ferron, Mathieu
影响因子:
29
作者:
Cawthorn WP;Scheller EL;Learman BS;Parlee SD;Simon BR;Mori H;Ning X;Bree AJ;Schell B;Broome DT;Soliman SS;DelProposto JL;Lumeng CN;Mitra A;Pandit SV;Gallagher KA;Miller JD;Krishnan V;Hui SK;Bredella MA;Fazeli PK;Klibanski A;Horowitz MC;Rosen CJ;MacDougald OA
通讯作者:
MacDougald OA